Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study

Petitdidier Nicolas; Tannoury Jenny; deAngelis Nicola; Gagniere Charlotte; Hulin Anne; Rotkopf Hugo; Mesli Farida; Brunetti Francesco; Sobhani Iradj; Amiot Aurelien

首页> 外文期刊>Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver >Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study

【24h】

Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study

机译：从英夫利昔单抗切换到炎症性肠病患者生物仿制性CT-P13后的患者的观点：一个12个月的前瞻性队列研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Patients' perspectives after switching from infliximab to a biosimilar have yet to be assessed.

机译：背景：患者从英夫利昔单抗切换到生物仿制物后的患者的观点尚未得到评估。

著录项

来源
《Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver》 |2019年第12期|共9页
作者
Petitdidier Nicolas; Tannoury Jenny; deAngelis Nicola; Gagniere Charlotte; Hulin Anne; Rotkopf Hugo; Mesli Farida; Brunetti Francesco; Sobhani Iradj; Amiot Aurelien;
展开▼
作者单位

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Gastroenterol EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Gastroenterol EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Digest Surg EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Gastroenterol EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Lab Pharmacol EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Gastroenterol EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Gastroenterol EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Digest Surg EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Gastroenterol EC2M3 EA 7375;

Paris Est Creteil UPEC Val de Marne Univ Henri Mondor Hosp APHP Dept Gastroenterol EC2M3 EA 7375;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
Biosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Infliximab; Ulcerative colitis;

机译：BioSimilar;克罗恩病;CT-P13;炎症性肠病;英夫利昔单抗;溃疡性结肠炎;

相似文献

外文文献
中文文献
专利

1. Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study [J] . Petitdidier Nicolas, Tannoury Jenny, deAngelis Nicola, Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver . 2019,第12期

机译：从英夫利昔单抗切换到炎症性肠病患者生物仿制性CT-P13后的患者的观点：一个12个月的前瞻性队列研究
2. Clinical Outcomes Following a Switch from RemicadeA (R) to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study [J] . Smits Lisa J. T., Derikx Lauranne A. A. P., de Jong Dirk J., Journal of Crohn’s & colitis . 2016,第11期

机译：在炎症性肠病患者中从RemicadeA（R）切换到生物仿制药CT-P13后的临床结果：一项前瞻性观察性队列研究
3. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study [J] . Schmitz E. M. H., Boekema P. J., Straathof J. W. A., Alimentary pharmacology & therapeutics. . 2018,第3期

机译：从炎症性肠病患者中从英夫利昔单抗创新者转换为生物素线：一个12个月的多长期观测前瞻性队列研究
4. Increased risk of morbidity associated with immunomodulatory treatment in patients with inflammatory bowel diseases [C] . J.-F. COLOMBEL, M. TORUNE Falk Symposium . 2007

机译：炎症性肠病患者的发病率增加了与免疫调节治疗有关的发病危险
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease [O] . María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, 2018

机译：在炎症性肠病患者中从原来的英夫利昔单抗转为英夫利昔单抗生物仿制药（CT-P13）的疗效和安全性丧失
7. P724 Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE) [O] . A Strik, W van de Vrie, J Bloemsaat-Minekus, 2018

机译：P724在静态炎症肠病患者从发起者intiximab切换到生物仿制剂CT-P13后，P724不变的英夫利昔单抗血清浓度：术前研究的结果（安全）

Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study

摘要

著录项

相似文献

相关主题

期刊订阅